» Articles » PMID: 20501751

Risk Factors for Ductal, Lobular, and Mixed Ductal-lobular Breast Cancer in a Screening Population

Overview
Date 2010 May 27
PMID 20501751
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Biological distinctions between histologic subtypes of breast cancer suggest etiologic differences, although few studies have been powered to examine such differences. We compared associations between several factors and risk of ductal, lobular, and mixed ductal-lobular breast cancers.

Methods: We used risk factor data from the Breast Cancer Surveillance Consortium for 3,331,744 mammograms on 1,211,238 women, including 19,119 women diagnosed with invasive breast cancer following mammography (n = 14,818 ductal, 1,602 lobular, and 1,601 mixed ductal-lobular). Histologic subtype-specific risk factor associations were evaluated using Cox regression.

Results: Significant positive associations with family history and breast density were similar across subtypes. Hormone therapy use was associated with increased risk of all subtypes, but was most strongly associated with lobular cancer [hazard ratio (HR) = 1.46; 95% confidence interval (CI), 1.25-1.70]. Relative to nulliparous women, parous women had lower risk of ductal and mixed but not lobular cancers (HR = 0.80; 95% CI, 0.76-0.84; HR = 0.79; 95% CI, 0.68-0.93; HR = 0.96; 95% CI, 0.81-1.15, respectively). Late age at first birth was associated with increased risk of all subtypes.

Conclusions: Similarities in risk factor associations with ductal, lobular, and mixed breast cancer subtypes were more pronounced than differences. Distinctions between subtype-specific associations were limited to analyses of hormone therapy use and reproductive history.

Impact: The results of this study indicate that the strongest risk factors for breast cancer overall (that is, family history and breast density) are not histologic subtype specific. Additional studies are needed to better characterize subtype-specific associations with genetic, hormonal, and nonhormonal factors.

Citing Articles

A Multi-Layer Breast Cancer Model to Study the Synergistic Effect of Photochemotherapy.

Flont M, Jastrzebska E Micromachines (Basel). 2023; 14(9).

PMID: 37763969 PMC: 10535669. DOI: 10.3390/mi14091806.


Correlation of Breast Density Grade on Mammogram With Diagnosed Breast Cancer: A Retrospective Cross-Sectional Study.

Sajjad B, Farooqi N, Rehman B, Khalid I, Urooj N, Sajjad S Cureus. 2022; 14(7):e27028.

PMID: 35989768 PMC: 9386336. DOI: 10.7759/cureus.27028.


Associations of coffee/caffeine consumption with postmenopausal breast cancer risk and their interactions with postmenopausal hormone use.

Yaghjyan L, McLaughlin E, Lehman A, Neuhouser M, Rohan T, Lane D Eur J Nutr. 2022; 61(7):3449-3459.

PMID: 35583696 PMC: 10227860. DOI: 10.1007/s00394-022-02899-8.


Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer.

Katuwal S, Tapanainen J, Pukkala E Breast Cancer Res Treat. 2022; 193(2):495-505.

PMID: 35366162 PMC: 9090885. DOI: 10.1007/s10549-022-06571-x.


Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma.

Timbres J, Moss C, Mera A, Haire A, Gillett C, Van Hemelrijck M Cancers (Basel). 2021; 13(12).

PMID: 34207042 PMC: 8234044. DOI: 10.3390/cancers13123036.


References
1.
Garcia-Closas M, Brinton L, Lissowska J, Chatterjee N, Peplonska B, Anderson W . Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer. 2006; 95(1):123-9. PMC: 2360503. DOI: 10.1038/sj.bjc.6603207. View

2.
Ballard-Barbash R, Taplin S, Yankaskas B, Ernster V, Rosenberg R, Carney P . Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol. 1997; 169(4):1001-8. DOI: 10.2214/ajr.169.4.9308451. View

3.
Li C, Daling J, Malone K, Bernstein L, Marchbanks P, Liff J . Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15(5):946-54. DOI: 10.1158/1055-9965.EPI-05-0881. View

4.
Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

5.
Slanger T, Chang-Claude J, Obi N, Kropp S, Berger J, Vettorazzi E . Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1188-96. DOI: 10.1158/1055-9965.EPI-09-0002. View